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Seunggeun Lee,1 Tanya M. Teslovich,2 Michael Boehnke,2 and Xihong Lin1,*
We propose a general statistical framework for meta-analysis of gene- or region-based multimarker rare variant association tests in
sequencing association studies. In genome-wide association studies, single-marker meta-analysis has been widely used to increase sta-
tistical power by combining results via regression coefficients and standard errors from different studies. In analysis of rare variants
in sequencing studies, region-based multimarker tests are often used to increase power. We propose meta-analysis methods for
commonly used gene- or region-based rare variants tests, such as burden tests and variance component tests. Because estimation of
regression coefficients of individual rare variants is often unstable or not feasible, the proposed method avoids this difficulty by calcu-
lating score statistics instead that only require fitting the null model for each study and then aggregating these score statistics across
studies. Our proposed meta-analysis rare variant association tests are conducted based on study-specific summary statistics, specifically
score statistics for each variant and between-variant covariance-type (linkage disequilibrium) relationship statistics for each gene or
region. The proposedmethods are able to incorporate different levels of heterogeneity of genetic effects across studies and are applicable
to meta-analysis of multiple ancestry groups.We show that the proposedmethods are essentially as powerful as joint analysis by directly
pooling individual level genotype data. We conduct extensive simulations to evaluate the performance of our methods by varying levels
of heterogeneity across studies, and we apply the proposedmethods to meta-analysis of rare variant effects in a multicohort study of the
genetics of blood lipid levels.Introduction
With the rapid advance of high-throughput sequencing
technologies,1 rare variant association analysis is increas-
ingly being conducted to identify genetic variants associ-
ated with complex traits. In recent years, significant effort
has been devoted to develop powerful and efficient statisti-
cal methods to test for such associations. Because single-
variant tests are underpowered to investigate rare variant
effects unless sample sizes or effect sizes are large,2
region-based multimarker tests have been commonly
used in an attempt to improve analysis power. For example,
collapsing or burden tests summarize rare variant informa-
tion within a gene or region into a single genetic score or
genetic burden before performing association analysis.3–5
Variance component tests such as C-alpha6 and SKAT7
aggregate individual variant test statistics in a gene or
region. Recently, unified tests that combine burden and
variance component tests have been proposed.8,9
In genome-wide association studies (GWASs) of com-
mon variants, a single study is often underpowered to
detect modest genetic effects.10 To overcome this limita-
tion, meta-analysis is routinely used to analyze data across
studies.11 Meta-analysis has several advantages over joint
analysis of individual level data. Because meta-analysis
uses study-specific summary statistics, it allows investiga-
tors to combine information across studies when individ-
ual-level data cannot be shared. Different studies often
require specific sets of covariates, which can be difficult
to accommodate in joint analysis. Finally, the summary
statistic data files are much smaller than individual level1Department of Biostatistics, Harvard School of Public Health, Boston, MA 02
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tests of common variants, it has been shown that meta-
analysis can be essentially as powerful as joint analysis.12
Hundreds of trait-associated common variants have been
discovered by meta-analysis.13–16
Detecting rare variant associations in sequencing studies
probably will often require even larger sample sizes than
common variant-oriented GWASs, making meta-analysis
important for the identification of rare susceptibility
alleles. However, little work has been done to develop
meta-analysis methods for gene- or region-based multi-
marker tests. Although existing single-marker methods
can be used for burden tests, no meta-analysis method
exists for variance component and unified tests.
For single-marker tests of common variants from
GWASs, meta-analysis typically analyzes regression coeffi-
cients and their standard errors across studies. However,
because of low minor allele frequencies, estimated regres-
sion coefficients of rare variants in multimarker regression
models are often unstable with very large variances, or
regression models often fail to converge in the presence
of many rare variants in a gene or region. Therefore, it is
important to develop meta-analysis methods for rare vari-
ants that do not require estimating regression coefficients
of rare variants.
In this paper, we propose a general framework for meta-
analysis for gene- or region-based rare variant analysis for
both continuous and binary traits. Unlike the traditional
regression coefficient-based single-marker meta-analysis,
a key advantage of the proposed method is that it
aggregates score statistics, avoiding the need to estimate115, USA; 2Department of Biostatistics and Center for Statistical Genetics,
y of Human Genetics. All rights reserved.
regression coefficients of rare variants. As variant compo-
nent score tests that require fitting only the null model,
the proposed methods are computationally efficient
even for whole-genome analysis, and p values can be
calculated analytically. Our meta-analysis framework
uses gene-level summary statistics and is applicable
to burden tests, variance component tests, and unified
tests. The proposed approach can accommodate different
levels of heterogeneity of genetic effects across studies,17
including between-ancestry heterogeneity,18 while
achieving power similar to that of joint analysis. We eval-
uate the performance of the proposed methods through
computer simulation and analysis of Metabochip array
data for eight European cohorts to assess association of
rare variants in lipoprotein lipase (LPL [MIM 609708])
gene with serum lipids.Methods
Burden Tests, SKAT, and SKAT-O for a Single Study
Suppose one conducts ameta-analysis with K studies and performs
a region- or gene-based analysis of rare variants. For the kth study,
nk subjects are sequenced in a region that hasmk variants. Let yki be
the phenotype of the ith individual, let Gki ¼ ðgki1;/; gkimk Þ0 be a
vector of mk genotypes (gkij ¼ 0, 1, or 2) in the region, and let Xki
be a vector of qk covariates including an intercept.
We consider the linear regression model
yki ¼ X0kiak þG0kibk þ εki; εki  N

0; s2k

(Equation 1)
when phenotypes are continuous and the logistic regression
model
logitP

yki ¼ 1
 ¼ X0kiak þG0kibk (Equation 2)
when phenotypes are binary, where ak ¼ ðak1;/;akqk Þ0and
bk ¼ ðbk1;/; bkmk Þ0 are vectors of regression coefficients of covari-
ate and genetic effects, respectively. The null hypothesis of no
genetic association between variants in the region and the
phenotype is H0: bk ¼ 0.
Let Skj ¼
Pnk
i¼1gkijðyki  bmkiÞ=bfk be the score statistic of the jth
variant in linear (for continuous traits) or logistic (binary
traits) regression models, where bmki is the estimated mean
of yki under the null linear ðyki ¼ X0kiak þ εkiÞ or logistic
ðlogitPðyki ¼ 1Þ ¼ X0kiakÞ regressionmodel, and bfk ¼ bs2k for contin-
uous traits and bfk ¼ 1 for binary traits with bs2k being estimated
under the null linear model. For study k, the SKAT statistic for
testingH0: bk ¼ 0 is derived by assuming that the bkj has a distribu-
tion with mean 0 and variances w2kjt and calculating a variance
component score test for H0: t ¼ 0. The SKAT statistic7 is
Qk;SKAT ¼
Xmk
j¼1
w2kjS
2
kj;
where wkj is a weight for the variant j.
For example, Madsen and Browning (2009)4 proposed
wkj ¼ 1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MAFjð1MAFjÞ
p
to up-weight rarer variants, where
MAFj is the minor allele frequency of variant j. Note that they esti-
matedMAFj by using only control samples in case-control studies.
Wu et al. (2011)7 proposed the flexible beta density function wkj ¼
Beta(MAFj, a1,a2) as weights with MAFj being estimated based onTheall study participants. The burden test statistic using the same
weight first aggregates the rare variants in the region and then
regresses the phenotype yki on the weighted total number of rare
variants and can be written as
Qk;Burden ¼
 Xmk
j¼1
wkjSkj
!2
:
Recently, we9,19 proposed a unified approach that combines
SKAT and the burden test into one framework as
QkðrÞ ¼ ð1 rÞQk;SKAT þ r Qk;Burden;
a weighted average of the SKAT and burden test statistics. We
demonstrated that r can be interpreted as a pair-wise correlation
among the genetic effects coefficients bkj, that is, r ¼ corr(bkj, bkj’)
for js j0.19 The asymptotic null distribution of Qk(r) is a mixture
of chi-square distributions,20 and asymptotic p values can be
obtained analytically by the Davies method,21,22 which approxi-
mates the inverse of the characteristic function.
Because in practice an optimal r is not known, we proposed an
adaptive procedure SKAT-O to find an optimal r to maximize
power.9 The SKAT-O test statistic T ¼ min pk (r), where pk (r) is
the p value forQk(r). Hence, SKAT-O adaptively selects the optimal
linear combination of SKAT and the burden test statistics. We
derived the null distribution of the SKAT-O statistics; p values
can be calculated by a computationally efficient one-dimensional
numerical integration.19
Meta-analysis SKAT and SKAT-O
Input from Each Study
Single-variant meta-analysis can be conducted with study-specific
summary statistics, such as the SNP estimated regression coeffi-
cient and its standard error. This same approach can be applied
to meta-analysis by the burden test for rare variants, because
burden tests collapse or summarize the rare variants within in a
region into a single value. For a nonburden multimarker test,
such as C-alpha or SKAT, meta-analysis can still be performed
with summary statistics. However, additional summary statistics
are necessary for calculatingmeta-analysis p values. For meta-anal-
ysis of variance component-based rare variant tests, such as SKAT,
the required summary statistics for each study are the MAFs, the
score statistics (Skj) for each variant, and the regional between-
variant relationship matrix Fk.
Suppose Gk is an nk 3 mk genotype matrix, and
Xk ¼ ½X0k1;/;X0knk 
0 is an nk 3 qk covariate matrix. The between-
variant relationship matrix is
Fk ¼ G0kPkGk;
where Pk ¼ V1k V1k XkðX0kV1k XkÞ1X0kV1k is the projection
matrix accounting for the fact that the effects of covariates
Xk are estimated under the null model, Vk ¼ bs2kI for
continuous traits (where I is an identity matrix), and
Vk ¼ diag½bmk1ð1 bmk1Þ;/; bmknk ð1 bmknk Þ for binary traits.
We show that if Xk has only an intercept term, thenFk is essen-
tially the covariance matrix of themk genetic markers up to a scale
parameter. Suppose 4kjl is the (j,l) element ofFk. WhenXk has only
an intercept,
4kjl ¼
Xnk
i¼1

gkij  gkj

gkil  gkl

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where bvk is the estimated variance of yki and gkj is the mean of
variant j. Therefore, Fk is a scaled sample covariance matrix of
mk genetic markers up to the scale parameter bvk.
Meta-analysis Assuming Homogeneous Genetic
Effects across Studies
For simplicity, we here assume that all variants are observed in all K
studies, so that m ¼ m1 ¼. ¼ mk. We relax this assumption later.
When genetic effects are homogeneous across studies, the effect
size parameters b1 ¼ b2 ¼.¼ bK, consistent with the assumption
made for single-marker fixed-effect meta-analysis. Under this
assumption, we use the following test statistic for meta-analysis:
QhommetaSKAT ¼
Pm
j¼1
PK
k¼1
wkjSkj
2
; QmetaBurden ¼
 Pm
j¼1
PK
k¼1
wkjSkj
!2
; and
QhommetaðrÞ ¼ ð1 rÞQhommetaSKAT þ rQmetaBurden:
(Equation 3)
Whenr¼0,Qhom-meta(0) corresponds to themeta-analysis version
of SKAT, which first collapses the weighted score of the jth variant
across studies and then aggregates the squared collapsed score
statistics across the m variants within the region. When r ¼ 1,
Qhom-meta(1) corresponds to the meta-analysis burden test, which
assumes that the effects of the variants in a region are the same
for all the variants across studies. Qhom-meta-SKAT and Qmeta-Burden are
identical to the joint analysis SKAT and burden test statistics
assuming stratified covariate effects by study. In contrast to joint
analysis, in which the same set of covariates needs to be used for
all studies, the proposedmeta-analysis allows study-specific covari-
ates to be used.
SupposeWk ¼ diag[wk1, ., wkm] is an m 3 m diagonal matrix of
marker-specific weights, where wkj will typically be a function
of the MAF of SNP j. For example, wkj ¼ Beta(MAFj, a1,a2)7
and (l1, ., lm) are nonzero eigenvalues of Fr ¼ Lr‘(W1 F1
W1 þ. þWK FKWK) Lr, where Lr is a Cholesky decomposition
matrix of the compound symmetric matrix Rr ¼ (1- r) I þ r11‘,
that is, Lr Lr‘ ¼ Rr. It can easily be shown that the asymptotic
null distribution of Qhom-meta(r) is a mixture of chi-square distribu-
tions,
Pm
j¼1ljc
2
j;1, where c
2
j;1 are independent chi-square df ¼ 1
random variables (Appendix B). Therefore, asymptotic p values
can be calculated analytically by the Davies method.21,22
The homogeneous meta-analysis SKAT-O test statistic can be
approximated by a simple grid search. We set a grid of D points
0 ¼ r1 < r2 < . < rD ¼ 1, then Thom-meta ¼ min [ p(r1), ., p(rD)
], where p(r) is the p value of Qhom-meta(r). The asymptotic null dis-
tribution and the p value for Thom-meta can be obtained analytically
(Appendix C).Meta-analysis Assuming Heterogeneous Genetic
Effects across Studies
Genetic effects may be heterogeneous across studies because of
between-study heterogeneity, such as differences in ancestries.
To allow for such heterogeneity, we modify Equation 3 with an
assumption that effect sizes of markers in different studies are
independent and follow a common distribution. The meta-anal-
ysis SKAT test statistic allowing for heterogeneity is
Qhet-meta-SKAT ¼
Xm
j¼1
XK
k¼1
w2kjS
2
kj; (Equation 4)
and the corresponding test statistic of the unified SKAT and
burden test is44 The American Journal of Human Genetics 93, 42–53, July 11, 2013Qhet-metaðrÞ ¼ ð1 rÞQhet-meta-SKAT þ rQmeta-Burden; (Equation 5)which is derived assuming that the regression coefficients bkj have
correlation r for k s k0 or j s j0 (Appendix A). When r ¼ 0,
Qhet-meta(r) reduces to the heterogeneous meta-analysis SKAT
statistic Qhet-meta-SKAT. We use the same burden test statistic for
Qhom-meta(r) and Qhet-meta(r). The statistic Qhet-meta(r) can be viewed
as an extension of the random effects model based meta-analysis
for single variants.
In some meta-analyses, studies can be naturally grouped, for
example based on ancestry. In this case, we might assume that
genetic effects for the same ancestry group are homogeneous,
whereas those for different ancestries are heterogeneous.18 Sup-
pose K studies can be grouped into B ancestries and there are Kb
studies in the bth ancestry group. The first K1 studies belong to
the first ancestry group, the next K2 studies belong to the second
ancestry group, and so forth. Let ~Kb ¼ K1 þ/þ Kb with ~K0 ¼ 0.
Then the heterogeneous meta-analysis SKAT test statistic can be
written as
QhetmetaSKAT ¼
Xm
j¼1
XB
b¼1
0@ X~Kb
k¼~Kb1þ1
wkjSkj
1A2; (Equation 6)
which first collapses the weighted score statistic of the jth marker
across the studies in the same ancestry group and then aggregates
the squared collapsed scores across ancestry groups and the
m markers in the region. The corresponding unified test statistic
has the same form as Equation 5 with Qhet-meta-SKAT in Equation 6
instead of Equation 4. Clearly Equation 4 is a special case of Equa-
tion 5 in which B ¼ 1 and K1 ¼ K. The generalized heterogeneous
meta-analysis SKAT-O test statistic can be obtained as described in
the previous section. Detailed derivations of the asymptotic null
distributions for meta-analysis SKAT and SKAT-O are provided in
Appendices B and C.
Weights for Variants and Dealing with Missing
Variants
In rare variant analysis, MAF-based weighting schemes are often
used to improve power.4,7 When genetic effects are assumed to
be homogeneous across studies, the pooled estimates of MAFs
can be used to construct the common weights for all studies.
If studies are grouped based on ancestry, one can use ancestry-
specific MAF-based weights. Further, we may test for association
by using only a subset of variants selected based on bioinformat-
ics analysis,23,24 for example by restricting analysis to nonsy-
nonymous SNPs or constructing weights with Polyphen24
scores.
Some variants may be observed in only a subset of studies. If
variant j was not observed in study k, we set Skj ¼ 0 and 4kjl ¼
4klj ¼ 0 for all l ¼ 1, ., m, where 4kjl is the (j,l) element of Fk.
This corresponds to using a zero weight for the jth variant in the
kth study (wkj ¼ 0).
Numerical Simulations
To evaluate the proposed methods, we generated 10,000 Euro-
pean-like (EUR) and 10,000 admixed African-American-like (AA)
haplotypes of length 200 kb by using the calibrated coalescent
model.25 Because the average total exon length of a gene is
~3 kb,26 we randomly selected a 3 kb region for each simulated
data set and tested for association between the selected region
and phenotypes.
Table 1. Simulation Study Settings
Sample Sizesa Covariatesb
Scenario Pop.c Study 1 Study 2 Study 3 Study 1 Study 2 Study 3
Different Cohort Sizes
1 EUR 1,600 (800, 800) 2,200 (1,000, 1,200) 3,200 (1,800, 1,400) (X1, X2) (X1, X2) (X1, X2)
2 EUR 1,600 (800, 800) 2,200 (1,000, 1,200) 3,200 (1,800, 1,400) (X1) (X1, X2) (X1, X2, X2)
3 EURþAA 1,600 (800, 800) 2,200 (1,000, 1,200) 3,200 (1,800, 1,400) (X1) (X1, X2) (X1, X2, X2)
Equal Cohort Sizes
4 EUR 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) (X1, X2) (X1, X2) (X1, X2)
5 EUR 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) (X1) (X1, X2) (X1, X2, X2)
6 EURþAA 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) 2,400 (1,000, 1,400) (X1) (X1, X2) (X1, X2, X2)
aTotal sample sizes, with numbers of cases and controls in the parentheses for simulation of binary traits.
bNumber of covariates in each study.
cEUR refers to the scenario where all three studies had EUR samples. EUR þ AA refers to the scenario where studies 1 and 2 had EUR samples and study 3 had
AA samples.To assess test calibration and estimate power, we considered six
different scenarios (Table 1). Scenario 1 has three studies with the
same set of covariates and scenarios 2 and 3 have three studies
with different covariates. In scenarios 1 and 2, all studies were
comprised of EUR samples; in scenario 3, the first two studies
were comprised of EUR samples and the third study was comprised
of AA samples. Scenarios 1–3 allow different sample sizes for
different studies. Scenarios 4–6 are similar to scenarios 1–3 but
assume the same sample sizes for all studies.
We compared eight meta-analysis methods: SKAT-O and SKAT
assuming homogeneous genetic effects across studies (Hom-
Meta-SKAT-O and Hom-Meta-SKAT); SKAT-O and SKAT assuming
heterogeneous genetic effects across studies (Het-Meta-SKAT-O
and Het-Meta-SKAT); Fisher’s inverse chi-square27 and Stouffer’s
Z score28 methods based on individual study SKAT-O p values
(Meta-Fisher and Meta-Z); and fixed and random-effect model-
based meta-analysis burden tests (Meta-Burden and Meta-
Burden-RE). We used a grid search for in r values (0 % r% 1) for
Hom-Meta-SKAT-O, Het-Meta-SKAT-O, Meta-Fisher, and Meta-Z
analyses (Appendix C). For Meta-Z,30 Z scores of the kth study
were computed as Zk ¼ F1(1  pvaluek), where F is the standard
normal cumulative distribution function and pvaluek is the p value
of study k calculated by SKAT-O. The square roots of sample sizes
were used as weights when Z scores were combined.29 Stouffer’s
Meta-Z differs from the standard Z score method used in single-
variant meta-analysis29,30 that uses the study-specific signs of
the regression coefficients to compute Z scores. This standard sin-
gle-marker-based Z score method cannot be directly generalized to
multimarker tests because there is no obvious way to provide a
sign for the jointmultimarker effects.We used the inverse variance
weighting for Meta-Burden and the REML estimation of variance
component for Meta-Burden-RE via the metafor package.31
For all methods, we used beta(MAF; 1, 25) weights to up-weight
rare variants (Figure S2 available online). We used MAF estimates
pooled across all study cohorts to construct weights for Hom-
Meta-SKAT and Hom-Meta-SKAT-O and used cohort-specific
MAFs for Het-Meta-SKAT and Het-Meta-SKAT-O analyses, except
for scenarios 3 and 6 where we used MAF estimates pooled within
ancestry groups. Because the other methods cannot use common
or ancestry-specific weights, we used cohort-specific weights.TheType I Error and Power Simulations
We generated continuous phenotypes according to the linear
model
yki ¼ 0:5Xk1i þ/þ 0:5Xkqki þG0ki;causalbk;causal þ εki; εki  Nð0;1Þ;
and binary phenotypes according to the logistic model
logitP

yki ¼ 1
 ¼ a0k þ 0:5Xk1i þ/þ 0:5Xkqki þG0ki;causalbk;causal;
where Gki,causal is a genotype vector containing the causal variants
and bk,causal is a vector of regression coefficients of genetic effects
of the causal variants. X1k is a binary covariate taking values
0 and 1 each with probability 0.5, other covariates were contin-
uous and distributed as standard normal, and qk indicates the
number of covariates for study k (Table 1). For the binary trait sim-
ulations, we chose the intercept a0k to correspond to prevalence
0.01 or 0.10 when there was no genetic effect, and retrospective
case-control phenotypes were generated, where the numbers of
cases and controls are given in Table 1.
For type I error simulations, we set bk,causal ¼ 0. To reduce the
computational burden at stringent a levels, we first generated
50,000 genotype sets for randomly selected regions and then
generated 500 phenotype sets for each genotype set. We set a ¼
2.5 3 106, 104, and 102, corresponding to genome-wide
studies of 20,000 genes and candidate gene studies of 500 and
5 genes.
For power simulations, we assumed that 5%, 10%, 20%, or 50%
of rare variants were causal. For each setting, we assumed either all
causal SNPs were of positive effect or 80% were positive and 20%
negative. Because it is possible that rarer variants have larger effect
sizes, we modeled genetic marker regression coefficients as b ¼
cjlog10(MAF)j. For continuous traits, we set c ¼ 0.25 when 20%
of the rare variants were causal, which gave effect size jbj ¼ 0.38
at MAF ¼ 0.03. We used c ¼ 0.475, c ¼ 0.375, and c ¼ 0.175,
when 5%, 10%, and 50% of the rare variants were causal variants
to compensate for the increased and decreased number of causal
variants. For binary trait simulations, we used c ¼ 0.35, when
20% of the rare variants were causal, which gave OR ¼ 1.7 at
MAF ¼ 0.03. We used c ¼ 0.6, c ¼ 0.46, and c ¼ 0.27, when 5%,
10%, and 50% of the rare variants were causal. For eachAmerican Journal of Human Genetics 93, 42–53, July 11, 2013 45
Table 2. Type I Error Rate Estimates at Different a Levels via Simulation Studies under Scenarios 1–3 Based on 2.5 3 107 Simulations
Scenarios Level a Hom-Meta-SKAT-O Hom-Meta-SKAT Het-Meta-SKAT-O Het-Meta-SKAT
Continuous Trait
Scenario 1 102 1.12 3 102 1.02 3 102 1.08 3 102 1.03 3 102
104 1.24 3 104 1.07 3 104 1.06 3 104 1.12 3 104
2.5 3 106 3.16 3 106 3.12 3 106 2.00 3 106 3.16 3 106
Scenario 2 102 1.14 3 102 1.02 3 102 1.10 3 102 1.05 3 102
104 1.27 3 104 1.10 3 104 1.05 3 104 1.16 3 104
2.5 3 106 3.32 3 106 2.84 3 106 2.20 3 106 3.32 3 106
Scenario 3 102 1.13 3 102 1.04 3 102 1.13 3 102 1.06 3 102
104 1.17 3 104 1.10 3 104 1.10 3 104 1.14 3 104
2.5 3 106 2.76 3 106 3.44 3 106 2.52 3 106 3.00 3 106
Binary Trait
Scenario 1 102 1.10 3 102 0.98 3 102 1.04 3 102 0.97 3 102
104 1.14 3 104 0.96 3 104 0.90 3 104 0.87 3 104
2.5 3 106 2.56 3 106 2.24 3 106 1.52 3 106 1.88 3 106
Scenario 2 102 1.12 3 102 0.99 3 102 1.05 3 102 0.96 3 102
104 1.13 3 104 0.94 3 104 0.86 3 104 0.86 3 104
2.5 3 106 2.64 3 106 2.00 3 106 1.68 3 106 2.04 3 106
Scenario 3 102 1.08 3 102 0.99 3 102 1.07 3 102 0.97 3 102
104 0.99 3 104 0.92 3 104 0.90 3 104 0.89 3 104
2.5 3 106 1.80 3 106 1.68 3 106 1.24 3 106 1.56 3 106
Each entry represents a type I error rate estimate calculated by the proportion of empirical p values smaller than the given level a.simulation setting, we generated 1,000 data sets. Power was esti-
mated as the fraction of p values less than a ¼ 2.5 3 106, 104,
and 102.Rare Variant Association Meta-analysis of Lipid Traits
in Eight European Cohorts
We analyzed data from eight studies collected in Northern and
Western Europe: from Finland we used D2D 2007, METSIM,
FUSION Stage 2, DPS, and DR’s EXTRA; from Norway, HUNT
and Tromsø; and from Germany, DIAGEN (Table S3). Samples
were collected according to protocols approved by local institu-
tional review boards, and all individuals provided informed con-
sent. DNA samples were genotyped on the Metabochip, a custom
genotyping array that includes SNPs to fine map 257 known
associations for cardiometabolic traits.32 Genotyping was per-
formed at the Center for Inherited Disease Research (CIDR) and
genotypes called with BeadStudio Genotyping Module, v.3.3.7.
We excluded samples and SNPs with call rate < 98% and excluded
one member of each of 970 first- and second-degree relative
pairs identified via KING.33 For illustration, we selected LPL, a
gene known to play a role in lipid biology. We identified seven
UTR and protein-coding SNPs with MAF < 0.05 (Table S2) and
analyzed them for association with HDL cholesterol, LDL choles-
terol, and triglycerides (TG).
The two Norwegian cohorts were analyzed jointly, with a covar-
iate for study origin; all other cohorts were analyzed individually.
Age, age2, sex, and type 2 diabetes status were included as covari-46 The American Journal of Human Genetics 93, 42–53, July 11, 2013ates, except for METSIM, which is comprised only of males.
Because LPL was selected based on association with the common
variant rs12678919 and we sought to identify independent asso-
ciation signals arising from rare variants in addition to common
variants, we included rs12678919 genotype as a covariate. For
each study, we performed inverse normal transformations on
the residuals of a linear regression of raw (HDL and LDL) or log-
transformed (TG) phenotypes on the covariates. Total sample
sizes were 11,438; 10,619; and 11,004 for HDL, LDL, and TG,
respectively.Results
Type I Error Simulation Results
For these studies of 7,000 individuals, empirical type I error
rates of the proposed Meta-SKAT and Meta-SKAT-O
approaches are given in Table 2. The MAF spectrum of
population allele frequencies in the simulated data
(Figure S1) shows that the majority of variants were very
rare. For example, 86% and 76% of variants in EUR had
population MAF < 0.01 and < 0.001. Type I error rates
were well controlled at significance levels a ¼ 102 and
104 for both continuous and binary phenotypes. At a ¼
2.5 3 106, type I error rates were slightly inflated for
continuous traits (with the exception of Het-Meta-SKAT-O)
and slightly deflated for binary traits.
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Figure 1. Comparisons ofMeta and Joint
Analysis of SKAT and SKAT-O
Sixteen dots represent sixteen combina-
tions of scenarios (scenarios 1 and 4), the
percentage of causal variants (5%, 10%,
20%, and 50%), and the percentage of
risk-decreasing variants (0% and 20%).
Empirical powers were obtained at a ¼
2.5 3 106.
(A) Comparison of Hom-Meta-SKAT and
joint analysis SKAT.
(B) Comparison of Hom-Meta-SKAT-O and
joint analysis SKAT-O.Power Simulation Results
To investigate the effect on power of different degrees of
heterogeneity of genetic effects across studies, we consid-
ered six scenarios (see Methods). The average numbers of
observed variants ranged from 42 to 47 and the sum of
causal allele MAFs from 0.003 to 0.07 (Table S1). Under
scenario 3, EUR and AA cohorts shared on average 2.2%,
3.5%, 7%, and 17% of causal variants when 5%, 10%,
20%, and 50% of variants were causal.
We first compared power of the proposed meta-analysis
methods with individual level data joint analysis. Figure 1
shows that for scenarios 1 and 4, the power of meta-anal-
ysis via Hom-Meta-SKATand Hom-Meta-SKAT-O are nearly
identical to those for joint analysis via SKAT and SKAT-O.
We considered scenarios 1 and 4 only because the other
scenarios allowed studies to have different sets of covari-
ates, which creates difficulties in applying joint analysis.
Figure 2 compares the performance of the proposed and
competing meta-analysis methods in a situation in which
all causal variants were risk increasing. The performance of
the methods varied depending on the degree of heteroge-
neity of genetic effects and the percentage of causal vari-
ants. When genetic effects were homogeneous across
studies (scenario 1), the methods assuming homogeneous
genetic effects (Hom-Meta-SKAT-O and Hom-Meta-SKAT)
were more powerful than those assuming heterogeneous
genetic effects (Hom-Meta-SKAT-O and Hom-Meta-SKAT),
although the power loss via Het-Meta-SKAT-O was modest.
When study cohorts shared about 50% of causal variants
(scenario 2), both approaches had comparable power.
When EUR and AA ancestry groups were more heteroge-
neous so that they shared only a small fraction of causal
variants (scenario 3), the methods that accounted for
ancestry-specific heterogeneity (Het-Meta-SKAT-O and
Het-Meta-SKAT) were substantially more powerful than
themethods assuming homogeneous genetic effects. Over-
all, Meta-Fisher had similar but slightly lower power than
Het-Meta-SKAT-O. When 5%, 10%, and 20% of rare
variants were causal, both Hom-Meta-SKAT and Het-
Meta-SKAT had higher power than Meta-Burden and vice
versa when the percentage of causal variants was 50%.
In contrast, Hom-Meta-SKAT-O, Het-Meta-SKAT-O, and
Meta-Fisher had robust power regardless of the percentageTheof causal variants, because they adaptively select the best
test in the class of tests that are a linear combination of
SKAT and burden test statistics.
Figure 3 compared the performance of the tests in the
presence of both risk-increasing and risk-decreasing vari-
ants. As expected, the power for Meta-Burden was substan-
tially reduced when 20% of causal variants were risk
decreasing. The power of meta-analysis SKAT and SKAT-O
methods were robust in this case, although powers
decreased slightly compared to the case in which all causal
variants were risk increasing (Figure 2). The conclusions on
the relative performances betweenHom-SKAT/SKAT-O and
Het-SKAT/SKAT-O were similar to the case when all causal
variants were risk increasing.
Power results for scenarios 4–6 with equal sample sizes
per group (Figures S3 and S4) and simulations assuming
prevalence 0.10 rather than 0.01 (Figures S5 and S6)
yielded the same conclusions regarding methods compari-
sons. We also compared power at a ¼ 102 and 104 and
results were the qualitatively the same (data not shown).
Power results for Meta-Z and Meta-Burden-RE for sce-
narios 1–3 (Figures S7 and S8) showed that Meta-Z was
slightly more powerful than Meta-Fisher when the genetic
effects were homogeneous (scenario 1) but less powerful
than Meta-Fisher when the genetic effects were heteroge-
neous (scenarios 2 and 3). Meta-Burden-RE was substan-
tially less powerful than the other methods.
In summary, the simulation results show that proper
modeling of heterogeneity of genetic effects can increase
the power of meta-analysis. Hom-Meta-SKAT-O was the
most powerful and robust test when genetic effects were
homogeneous, although the loss of power via Het-Meta-
SKAT-O ismodest.Het-Meta-SKAT-Owas themost powerful
and robust test when genetic effects were heterogeneous.
The simulation results also show that the proposed
methods are flexible in accounting for a range of heteroge-
neity of genetic effects between studies and are as powerful
as joint analysis with all individual level data.
Rare Variant Association Meta-analysis of Lipid Traits
in Eight European Cohorts
We applied our meta-analysis methods to analysis of the
multicohort lipid data. We investigated the associationAmerican Journal of Human Genetics 93, 42–53, July 11, 2013 47
Figure 2. Power Comparisons of the Six Competing Methods when All Causal Variants Were Risk Increasing
Empirical power at a ¼ 2.5 3 106 with different study cohort sizes (Table 1) when all causal variants in a region were risk increasing.
Hom-Meta-SKATandHom-Meta-SKAT-O used the sameweights for different studies calculated with the pooledMAF estimates andMeta-
Fisher and Meta-Burden used the study-specific weights. In scenarios 1 and 2, Het-Meta-SKAT and Het-Meta-SKAT-O were conducted by
assuming study-specific heterogeneity with study-specific weights. In scenario 3, Het-Meta-SKAT and Het-Meta-SKAT-O were conducted
by assuming ancestry-specific heterogeneity with ancestry-specific weights. For each scenario, we considered three settings by randomly
selecting 5%, 10%, 20%, and 50%of variants withMAF< 3% in a randomly selected 3 kb region as causal variants. For causal variants, we
assumed that b¼ cjlog10(MAF)j. Different c values were used for three different percentages of causal variants (seeMethods). Therefore the
power across the three settings (5%, 10%, 20%, and 50% of variants being causal) in each figure are not comparable.between seven identified low-frequency and rare protein-
coding and UTR variants in LPL with the three serum lipid
phenotypes after adjusting for the common LPL variant
rs12678919 previously shown to be associated with HDL
and TG.13 For Het-Meta-SKAT and Het-Meta-SKAT-O, we
assumed study-specific heterogeneous genetic effects by
using Equation 4 (Table 3). Het-Meta-SKAT (p values ¼
6.5 3 105 and 1.5 3 105) and Het-Meta-SKAT-O
(p values ¼ 1.4 3 104 and 3.5 3 105) had the smallest
p values for HDL and TG. The estimated optimal r of
Het-Meta-SKAT-O for both HDL and TG was zero, corre-
sponding to the SKAT test, which explains why Het-
Meta-SKAT yielded smaller p values than Het-Meta-SKAT-
O. None of the meta-analysis methods suggested strong
association of LPL variants with LDL, consistent with the
results for common variants in GWASs. Interestingly, the
p values of Hom-Meta-SKAT and Hom-Meta-SKAT-O were
substantially larger than the p values of Het-Meta-SKAT
and Het-Meta-SKAT-O, consistent with the presence of48 The American Journal of Human Genetics 93, 42–53, July 11, 2013heterogeneity of the genetic effects of LPL across the
studies. Meta-Z had larger p values than Meta-Fisher, and
all p values of Meta-Burden-RE were >0.05 (data not
shown).
We also applied single-variantmeta-analysis methods for
the seven LPL SNVs individually (Table S2). The minimum
p value among the seven SNPs was 5.5 3 103 for HDL
and 1.3 3 104 for TG, which, even without correction for
multiple comparisons, was substantially less significant
than p values of Het-Meta-SKAT and Het-Meta-SKAT-O.
To estimate the trait variance explained by seven genetic
variants in LPL, we computed adjusted R-squares by fitting
standard linear regression, because the variants were not
extremely rare on the Metabochip; all variants were pre-
sent in at least two copies. When the seven rare variants
were included in linear models, the adjusted R-squares
were 0.32% and 0.44% for HDL and TG, after adjusting
for covariates and SNV rs12678919. If all 20 exon and
UTR SNVs were used, the adjusted R-squares were 0.88%
Figure 3. Power Comparisons of the Six Competing Methods when 20%/80% of Causal Variants Were Risk-Decreasing/Risk-
Increasing
Empirical power at a¼ 2.53 106 with different study cohort sizes (Table 1) assuming 20%of the causal variants were risk decreasing and
80% of the causal variants were risk increasing. Hom-Meta-SKAT and Hom-Meta-SKAT-O used the same weights for different studies
calculated via the pooled MAF estimates, and Meta-Fisher and Meta-Burden used the study-specific weights. In scenarios 1 and 2,
Het-Meta-SKATand Het-Meta-SKAT-O were conducted by assuming study-specific heterogeneity with study-specific weights. In scenario
3, Het-Meta-SKATandHet-Meta-SKAT-Owere conducted by assuming ancestry-specific heterogeneity with ancestry-specific weights. For
each scenario, we considered three settings by randomly selecting 5%, 10%, 20%, and 50% of variants with MAF < 3% in a randomly
selected 3 kb region as causal variants. For causal variants, we assumed that b ¼ cjlog10(MAF)j. Different c values were used for three
different percentages of causal variants (see Methods). Therefore the power across the three settings (5%, 10%, 20%, and 50% of variants
being causal) in each figure are not comparable.and 1.21% for HDL and TG, respectively. These results
show that only a small proportion of trait heritability
was explained by the rare variants in LPL typed on the
Metabochip.Discussion
In this paper, we propose a statistical framework for meta-
analysis of rare variant effects via burden tests, variance
component tests, and unified tests that combine features
of both. The framework is based on study-specific sum-
mary statistics for each region and is flexible enough to
accommodate a range of heterogeneity of genetic effects
across studies, including ancestry-specific heterogeneity
for multiethnic studies. The power simulations and lipids
data example demonstrate that power of the proposedThemeta-analysis framework is maximized when hetero-
geneity of genetic effects is properly modeled. From
our simulation studies, we have found that Het-Meta-
SKAT-O is reasonably robust to heterogeneity of genetic
effects across studies; it is powerful when genetic
effects are heterogeneous and loses little power when
genetic effects are homogeneous across studies. The lipid
data example shows that Het-Meta-SKAT-O works well in
practice.
We note that the Hom-Meta-SKAT and Hom-Meta-
SKAT-O test statistics assuming homogeneous genetic
effects are essentially identical to joint analysis test statistics
using all individual level data accounting for study-specific
covariate effects, resulting in nearly identical power using
meta-analysis and joint analysis. Our power simulations
confirm this finding. Meta-analysis has several additional
advantages over traditional individual data-based jointAmerican Journal of Human Genetics 93, 42–53, July 11, 2013 49
Table 3. Analysis Results of the Multicohort Lipid Data for Testing the Effect of LPL on the Lipid Traits via Different Rare-Variant Meta-
analysis Methods
Trait Hom-Meta-SKAT-O Hom-Meta-SKAT Het-Meta-SKAT-O Het-Meta-SKAT Meta-Fisher Meta-Burden
HDL 2.5 3 102 1.7 3 102 1.4 3 104 6.5 3 105 1.8 3 102 3.5 3 101
LDL 1.0 8.3 3 101 4.0 3 101 2.5 3 101 3.9 3 101 2.1 3 102
TG 5.3 3 103 3.7 3 103 3.5 3 105 1.5 3 105 6.0 3 104 7.7 3 102
Het-Meta-SKAT achieved the smallest p values for traits HDL and TG.analysis. It avoids the need to share individual level data
(requiring only summary statistics), allows one to adjust
for different sets of covariates for different studies, and
allows for heterogeneous genetic effects between studies.
Liu et al. (2013)34 have recently independently developed
meta-analysis burden and variance component tests that
are analogous to our Meta-Burden and Hom-Meta-SKAT
for continuous traits in addition to meta-analysis variable-
threshold test.5
In contrast to joint analysis, which requires sharing of
individual-level data, the proposed gene- or region-based
multimarker tests require sharing of only summary statis-
tics: single marker score statistics and between-variants
relationship matrices that represent the linkage disequilib-
rium (LD) structure of the target regions. Although it is
possible to estimate LD structure by using publicly
available reference samples from the HapMap35 or 1000
Genomes32 Project for common variants,36 this approach
is less effective for rare variant analysis, because these
relationships may be more variable and because many
rare variants may not even be observed in the reference
samples. Future research is needed to determine the impact
of using an external reference panel to estimate LD for rare
variant meta-analysis.
Our Hom-Meta-SKAT and Hom-Meta-SKAT-O are multi-
marker score statistics analogous to that used in single-
variant fixed-effects meta-analysis, and Het-Meta-SKAT
and Het-Meta-SKAT-O are multimarker score statistics
analogous to that used in single-variant random-effects
meta-analysis.37 However, for a single marker, our Het-
Meta-SKAT and Het-Meta-SKAT-O statistics do not reduce
to that used in the traditional single-variant random
effects model. Specifically, our null hypothesis assumes
that study-specific population heterogeneous genetic
effects are all zero, whereas the test used in the traditional
single-variant random effect meta-analysis assumes that
the overall mean is zero but allows study-specific effects
to randomly vary around zero under the null. In this
regard, our approach can be viewed as a multimarker
extension of the modified single-variant random-effect
model meta-analysis test proposed by Han and Eskin.37
The difference is that the score statistics are used instead
of the likelihood ratio statistics and multiple markers are
used instead of a single marker. Han and Eskin37 have
shown that for single variants, the modified approach
can have improved power over the traditional random
effects model meta-analysis test and the fixed effect50 The American Journal of Human Genetics 93, 42–53, July 11, 2013meta-analysis test in the presence of heterogeneous SNP
effects. Our findings are consistent in this regard in multi-
marker settings.
One of the important features of the proposed meta-
analysis framework is that it allows for flexible modeling
of the degree of heterogeneity of genetic effects across
studies. For multiethnic studies, the proposed framework
allows for mixed homogeneous and heterogeneous genetic
effects across different ancestry groups. By using simula-
tion and real data analysis, we have shown that the power
can be improved by properly modeling the heterogeneity
of genetic effects. It is of future research interest to develop
a test to examine whether gene-level effects are heteroge-
neous across studies.
In traditional single-variant meta-analysis of common
variants, regression coefficients for the variant in each
study are often used. Because sequencing studies consist
of a large number of rare variants, estimation of the effects
of rare variants by traditional regression methods is unsta-
ble with very large variances or often infeasible for both
individual studies and meta-analysis when, for example,
some rare variants are present in some studies but not
all studies. An important advantage of our proposed
meta-analysis methods is that they overcome this diffi-
culty by using score statistics that do not require esti-
mating regression coefficients of individual variants and
only require fitting the null models. Our methods also
allow p values to be calculated analytically, making our
methods computationally fast even when analyzing data
genome-wide. Our simulation study shows that our ana-
lytic p value calculations are quite accurate except when
the nominal type I error is very low (a ¼ 2.5 3 106),
where the estimated type I error is slightly inflated for
continuous traits and slightly deflated for binary traits.
In future research, we plan to develop more accurate ana-
lytic p value calculations for very small type I error rates
for the proposed methods, perhaps by using resampling
methods, and to develop methods beyond traditional
regression methods to estimate rare-variant effects in indi-
vidual sequencing association studies and meta-analysis
of multiple sequencing studies.
With rapid advances of sequencing technologies, more
sequencing data from various existing large cohorts will
be collected and more meta-analysis will be conducted in
diverse populations. Our flexible meta-analysis framework
provides an effective approach for rare-variant analysis
across multiple and diverse studies.
Appendix A: Derivation of Qhet-meta (r)
Equations 1 and 2 can be written as the following general-
ized linear model with a canonical link function hð,Þ:
h

E

yki
 ¼ X0kiak þG0kibk; (Equation A1)
where hð,Þ is an identity function for continuous traits
and a logistic function for binary traits. We assume that
coefficients bkjs are random variables with
E

bkj
 ¼ 0; Varbkj ¼ tw2kj; and corrbkj; bk0 j0 ¼ r
(Equation A2)
for jsj0 or ksk0. Equation A1 can be rewritten as24hEy1hEy2
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Let yk ¼ ðyk1;/; yknkÞ0 be a vector of nk phenotypes andbmk ¼ ðbmk1;/; bmknkÞ be a vector of the estimated mean
of yk under the null hypothesis of no association, H0:
bk ¼ 0. A score test statistic of t ¼ 0 is
QhetmetaðrÞ ¼
PK
k¼1

yk  bmk0GkWkRrWkG0kyk  bmkbf2k
¼ ð1 rÞPm
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!2
;
(Equation A3)
where bfk ¼ bs2k for continuous traits and bfk ¼ 1 for binary
traits.
Next we derive Equation 5, which was obtained
assuming B ancestry groups with the bth group consisting
of Kb studies. We assume that bkj ¼ bk0j when both k and
k0 belong to the same ancestry. Otherwise, Equation A2
holds. Let bb ¼ ðbb1;.; bbmÞ be a vector of regression coef-
ficients of the ancestry group b. Via a matrix notation, the
generalized linear model is24 hEy1hEy2
«
h

E

yK

35 ¼ 2664X1 0 . 00 X2 . 0« « 1 «
0 0 . XK
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2666666664
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3775TheThe score test statistic of t ¼ 0 is
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(Equation A4)
One can easily see that when B ¼ 1, Equation A4 reduces
to Qhom-meta in Equation 3.Appendix B: Null Distribution of Qhom-meta (r)
and Qhet-meta (r)
Because Equation 5 is identical to Equations 3 and 4 for B¼
1 and B ¼ K, respectively, we only need to derive the null
distribution of Equation 5. Let Sk ¼ ðwk1Sk1;.;wkmSkmÞ0
and ~Sb ¼
P~Kb
k¼~Kb1þ1
Sk, and then ~Sb asymptotically follows
a multivariate Gaussian distribution with mean zero and
variance ~Fb ¼
P~Kb
k¼~Kb1þ1
WkFkWk. We further define
~S ¼ ð~S
0
1;/;
~S
0
BÞ0 and a block diagonal matrix
~F ¼
2664
~F1 0 . 0
0 ~F2 . 0
« « 1 «
0 0 . ~FB
3775;
which is the covariance matrix of ~S. By simple matrix
algebra, we can show
ðA4Þ ¼ ð1 rÞ~S0~Sþ r~S0 110 ~S ¼ ~S0Rr~S: (Equation B1)
It can be easily shown that Equation B1 asymptotically
follows a mixture of chi-square distribution
PBm
j¼1ljc
2
1;j,
where fljgs are nonzero eigenvalues of L0r ~FLr andc21;j are
independent and identically distrubuted chi-square
random variables with one degree of freedom (df). An
approximate p value of Qhet-meta (r) can be easily obtained
by the Davies method.22Appendix C: Null Distribution of Meta-SKAT-O
We only show the null distribution of Het-Meta-SKAT-O
based on Equation 5, because Equation 5 is identical to
Qhom-meta (r) when all studies belong to the same group.
The test statistic of Het-Meta-SKAT-O is
Thetmeta ¼ inf
0%r%1
pr; (Equation C1)
where pr is a p value ofQhet-meta (r). The test statistic Thet-meta
can be obtained by simple grid search across a range of r:
set a grid 0 ¼ r1 < r2 <. < rD ¼ 1, then the test statistic
Thetmeta ¼ minfpr1 ;.; prDg. To obtain the null distribution
of Thet-meta, we first define g ¼ 10 ~F1, A ¼ ~F110 ~F=g, andAmerican Journal of Human Genetics 93, 42–53, July 11, 2013 51
dðrdÞ ¼ rdgþ ð1 rdÞ10 ~F~F1 =g: Following the same logic
in Lee et al.,19 we show that under the null hypothesis
Qhet-meta (rd) is asymptotically identical to
ð1 rdÞ
 Xm
k¼1
lkhk þ z
!
þ dðrdÞh0 ¼ ð1 rdÞkþ dðrdÞh0;
(Equation C2)
where fl1;.lmg are nonzero eigenvalues of ~F A, hks are
i.i.d c21 random variables,k ¼
Pm
k¼1lkhk þ z, and z satisfies
the following conditions:
EðzÞ ¼ 0; VarðzÞ ¼ 4trace~FAA2;
Corr
Pm
k¼1
lkhk; z

¼ 0; and Corrðh0; zÞ ¼ 0:
Because the correlation between k and h0 is zero, we can
approximate Qhet-meta (r) as the mixture of two indepen-
dent random variables wherein h0 asymptotically follows
a chi-square distribution with df ¼ 1, and k can be asymp-
totically approximated to a mixture of chi-square distribu-
tions with a proper adjustment. Now, the p value of
Thet-meta can be quickly obtained by a one-dimensional
numerical integration.
In a previous paper, we showed that the optimal rfp21,
where p1 is a proportion of causal variants.
19We also found
that the unified test behaved similarlywhen r> 0.5.Hence,
we used a grid of eight values of r¼ (0, 0.12, 0.22, 0.32, 0.42,
0.52, 0.5, 1) toperformthe searchof theoptimalr in SKAT-O
and Meta-SKAT-O in simulation studies and real data
analysis. We also note that we modified the implementa-
tion of SKAT-O procedure to use the Davies method (rather
than a moment matching method) to get a minimum
p value over the grids of r values to improve the type I error
control in the extreme tails of the distribution.
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Supplemental Data include eight figures and three tables and can
be found with this article online at http://www.cell.com/AJHG/.
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